All In Biotech

Drug Trial Radar · NCT04090957

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)

A Randomized Double-blind Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study II)

Last checked: Nov 20, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,015 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,015

Actual

Start

Sep 27, 2019

Primary completion

Aug 18, 2022

Study completion Aug 18, 2022

Sponsor

Lead sponsor
EstetraIndustry
Sponsor type
Industry
Collaborators
ICON Clinical Research
First posted
Sep 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A two-part study designed to evaluate the effect of Estetrol (E4) 15 mg, 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) in the Efficacy Study Part and the safety of E4 20 mg in the Safety Study Part.

Conditions

  • Vasomotor Symptoms
  • Menopausal Symptoms

Interventions

  • Estetrol oral tabletDrug

    Estetrol oral tablet, administered orally once daily.

  • Placebo oral tabletDrug

    Placebo oral tablet, administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in Weekly Frequency of Moderate to Severe Vasomotor Symptoms (VMS) From Baseline to Week 4 and Week 12 -- (Efficacy Study Part)Time frame: Week 0 (Baseline), Week 4, Week 12.
  2. Mean Change in Severity of Moderate to Severe Vasomotor Symptoms (VMS) From Baseline to Week 4 and Week 12 -- (Efficacy Study Part)Time frame: Week 0 (Baseline), Week 4, Week 12.

Locations

117 sites in 2 countries. Site status is shown where the registry gives one.

  • Estetra Study Site

    Birmingham, Alabama

  • Estetra Study Site

    Birmingham, Alabama

  • Estetra Study Site

    Birmingham, Alabama

  • Estetra Study Site

    Dothan, Alabama

  • Estetra Study Site

    Phoenix, Arizona

  • Estetra Study Site

    Phoenix, Arizona

  • Estetra Study Site

    Tempe, Arizona

  • Estetra Study Site

    Tucson, Arizona

  • Estetra Study Site

    Tucson, Arizona

  • Estetra Study Site

    Tucson, Arizona

  • Estetra Study Site

    Tucson, Arizona

  • Estetra Study Site

    Little Rock, Arkansas

  • Estetra Study Site

    Bellflower, California

  • Estetra Study Site

    Canoga Park, California

  • Estetra Study Site

    Chula Vista, California

  • Estetra Study Site

    Huntington Beach, California

  • Estetra Study Site

    La Mesa, California

  • Estetra Study Site

    Lincoln, California

  • Estetra Study Site

    Los Angeles, California

  • Estetra Study Site

    Pomona, California

  • Estetra Study Site

    Sacramento, California

  • Estetra Study Site

    San Diego, California

  • Estetra Study Site

    San Diego, California

  • Estetra Study Site

    Santa Ana, California

  • Estetra Study Site

    Thousand Oaks, California

  • Estetra Study Site

    West Covina, California

  • Estetra Study Site

    Colorado Springs, Colorado

  • Estetra Study Site

    Denver, Colorado

  • Estetra Study Site

    Crystal River, Florida

  • Estetra Study Site

    Jacksonville, Florida

  • Estetra Study Site

    Jacksonville, Florida

  • Estetra Study Site

    Miami, Florida

  • Estetra Study Site

    Miami, Florida

  • Estetra Study Site

    Miami, Florida

  • Estetra Study Site

    Miami Lakes, Florida

  • Estetra Study Site

    New Port Richey, Florida

  • Estetra Study Site

    Ocoee, Florida

  • Estetra Study Site

    Orlando, Florida

  • Estetra Study Site

    Sarasota, Florida

  • Estetra Study Site

    West Palm Beach, Florida

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.